MIMETAS
@mimetas.bsky.social
We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models.
Customer spotlight at #SLAS2026
Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform!
Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing.
#OrganOnAChip #Automation
Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform!
Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing.
#OrganOnAChip #Automation
February 12, 2026 at 12:47 PM
Customer spotlight at #SLAS2026
Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform!
Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing.
#OrganOnAChip #Automation
Mayu Shibuta from Astellas Pharma showcased an Automated Organ-on-a-Chip Platform for Scalable Drug Testing using the OrganoPlate® platform!
Automation + Organ-on-a-Chip = scalable, reproducible, human-relevant drug testing.
#OrganOnAChip #Automation
Poster alert for #SLAS2026! Our collaborators at Tecan are presenting functional intestinal ADME/Tox testing using the MIMETAS OrganoReady® Colon Organoid Model + Tecan Spark Cyto.
📍Boston | Feb 11, 12–1 PM | Poster 1309-E
www.mimetas.com/organoready-...
#Organoids #ADMETox
📍Boston | Feb 11, 12–1 PM | Poster 1309-E
www.mimetas.com/organoready-...
#Organoids #ADMETox
February 11, 2026 at 10:38 AM
Poster alert for #SLAS2026! Our collaborators at Tecan are presenting functional intestinal ADME/Tox testing using the MIMETAS OrganoReady® Colon Organoid Model + Tecan Spark Cyto.
📍Boston | Feb 11, 12–1 PM | Poster 1309-E
www.mimetas.com/organoready-...
#Organoids #ADMETox
📍Boston | Feb 11, 12–1 PM | Poster 1309-E
www.mimetas.com/organoready-...
#Organoids #ADMETox
We’re proud to share that MIMETAS is a founding member of IAMPS, the world’s first industry alliance dedicated to advancing microphysiological systems (MPS).
With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
February 10, 2026 at 1:16 PM
We’re proud to share that MIMETAS is a founding member of IAMPS, the world’s first industry alliance dedicated to advancing microphysiological systems (MPS).
With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
With 8 other European innovators, IAMPS will accelerate regulatory acceptance, standardization & adoption of #NAMs. shorturl.at/dLRcF
Day 2 at #WORD+ 2026!
Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects.
Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects.
Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
February 5, 2026 at 10:10 AM
Day 2 at #WORD+ 2026!
Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects.
Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
Our team is ready to go at Booth #6 to discuss how MIMETAS' Organ-on-a-Chip models can not just support but accelerate your research projects.
Also, don't forget to check out our poster on Predicting Gastrointestinal Toxicity!
Great start at #WORD+2026! Today, Pleun Hombrink (Director of Bioproduction & Screening at MIMETAS) shared how integrating colon organoids with MPS can enable more predictive, scalable drug discovery.
Stop by booth #6 to meet the team!
#NAMsInAction #Organoids #OrganOnAChip #MPS
Stop by booth #6 to meet the team!
#NAMsInAction #Organoids #OrganOnAChip #MPS
February 4, 2026 at 2:10 PM
Great start at #WORD+2026! Today, Pleun Hombrink (Director of Bioproduction & Screening at MIMETAS) shared how integrating colon organoids with MPS can enable more predictive, scalable drug discovery.
Stop by booth #6 to meet the team!
#NAMsInAction #Organoids #OrganOnAChip #MPS
Stop by booth #6 to meet the team!
#NAMsInAction #Organoids #OrganOnAChip #MPS
We’re hiring a Junior Scientist at MIMETAS! 🧬
Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery.
📍 Leiden, NL
👉 Apply here: mimetas.easycruit.com/vacancy/3585...
#Hiring #LifeSciencesJobs #Biotech
Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery.
📍 Leiden, NL
👉 Apply here: mimetas.easycruit.com/vacancy/3585...
#Hiring #LifeSciencesJobs #Biotech
January 28, 2026 at 4:11 PM
We’re hiring a Junior Scientist at MIMETAS! 🧬
Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery.
📍 Leiden, NL
👉 Apply here: mimetas.easycruit.com/vacancy/3585...
#Hiring #LifeSciencesJobs #Biotech
Join our Model Development team in Leiden and work hands-on with cutting-edge organ-on-a-chip technology to shape the future of drug discovery.
📍 Leiden, NL
👉 Apply here: mimetas.easycruit.com/vacancy/3585...
#Hiring #LifeSciencesJobs #Biotech
Great discussions at Designing the Future Through Patient-Based Drug Development by Ombion.
Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
January 26, 2026 at 2:43 PM
Great discussions at Designing the Future Through Patient-Based Drug Development by Ombion.
Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
Our CEO Jos Joore presented on Enabling Human Biology in Regulatory Science, showing how fit-for-purpose #NAMs can strengthen regulatory decision-making and advance drug development.
💡 Publication spotlight:
Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling.
🔗 onlinelibrary.wiley.com/doi/10.1111/...
Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling.
🔗 onlinelibrary.wiley.com/doi/10.1111/...
Mechanisms of gut epithelial barrier impairment caused by food emulsifiers polysorbate 20 and polysorbate 80
This study provides new insights into the underlying mechanisms of intestinal epithelial barrier defects in response to commonly used food emulsifiers P20 and P80. We demonstrated that P20 and P80 di...
onlinelibrary.wiley.com
January 19, 2026 at 3:35 PM
💡 Publication spotlight:
Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling.
🔗 onlinelibrary.wiley.com/doi/10.1111/...
Swiss Institute of Allergy and Asthma Research researchers used the OrganoPlate® platform to develop Caco-2 and colon organoid models to study how food emulsifiers affect gut epithelial barrier integrity and inflammatory signaling.
🔗 onlinelibrary.wiley.com/doi/10.1111/...
🧠 Did you see the human BBB image we shared recently? In this webinar, learn how we develop a perfused human BBB model for disease modeling and DMPK studies, including stroke, neuroinflammation, toxicity testing, and drug transport: register.gotowebinar.com/register/189...
January 12, 2026 at 2:18 PM
🧠 Did you see the human BBB image we shared recently? In this webinar, learn how we develop a perfused human BBB model for disease modeling and DMPK studies, including stroke, neuroinflammation, toxicity testing, and drug transport: register.gotowebinar.com/register/189...
🧠 A fluorescence image of a human BBB model combining HBMECs, astrocytes, and pericytes. Claudin-5 (green), GFAP (red), and Hoechst (blue) reveal organized BBB architecture supporting studies of BBB function and drug transport. Discover the model: shorturl.at/APOzu
January 9, 2026 at 3:13 PM
🧠 A fluorescence image of a human BBB model combining HBMECs, astrocytes, and pericytes. Claudin-5 (green), GFAP (red), and Hoechst (blue) reveal organized BBB architecture supporting studies of BBB function and drug transport. Discover the model: shorturl.at/APOzu
New drug modalities bring new safety challenges.
Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3
#DrugDiscovery #Toxicology #OrganOnAChip
Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3
#DrugDiscovery #Toxicology #OrganOnAChip
January 6, 2026 at 3:43 PM
New drug modalities bring new safety challenges.
Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3
#DrugDiscovery #Toxicology #OrganOnAChip
Watch our on-demand webinar to learn how human 3D in vitro models & organ-on-a-chip improve toxicity prediction. shorturl.at/ONaf3
#DrugDiscovery #Toxicology #OrganOnAChip
Barrier dysfunction is key in gut disease and drug safety. Our study in MDPI Toxins shows a scalable, multi-parameter way to assess gut barrier integrity in MIMETAS' OrganoReady® gut models, supporting compound safety assessment and drug development.
🔗 www.mdpi.com/2072-6651/17...
🔗 www.mdpi.com/2072-6651/17...
December 31, 2025 at 10:19 AM
Barrier dysfunction is key in gut disease and drug safety. Our study in MDPI Toxins shows a scalable, multi-parameter way to assess gut barrier integrity in MIMETAS' OrganoReady® gut models, supporting compound safety assessment and drug development.
🔗 www.mdpi.com/2072-6651/17...
🔗 www.mdpi.com/2072-6651/17...
Merry Christmas🎄✨
Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉
See you in the New Year!
Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉
See you in the New Year!
December 24, 2025 at 3:20 PM
Merry Christmas🎄✨
Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉
See you in the New Year!
Thanks for being part of the MIMETAS journey in 2025 –good science, great collaborations, and yes… that website you may have already clicked through 😉
See you in the New Year!
The U.S. Senate has passed the FDA Modernization Act 3.0, moving FDA regulations closer to current nonclinical practice. The bill updates outdated “animal” testing language and supports broader use of human-relevant methods in drug development.
buddycarter.house.gov/news/documen...
buddycarter.house.gov/news/documen...
Carter-led bill reducing unnecessary animal testing passes Senate
Rep. Buddy Carter, Serving Georgia's 1st District
buddycarter.house.gov
December 18, 2025 at 3:10 PM
The U.S. Senate has passed the FDA Modernization Act 3.0, moving FDA regulations closer to current nonclinical practice. The bill updates outdated “animal” testing language and supports broader use of human-relevant methods in drug development.
buddycarter.house.gov/news/documen...
buddycarter.house.gov/news/documen...
Attivare Therapeutics (Wyss Institute spin-out) has joined Oncode Accelerator with a new Demonstrator Project, which MIMETAS is a key partner in.
Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
Wyss Institute Spin-Out Attivare Therapeutics Joins Oncode Accelerator to Advance Novel Cancer Therapeutics | Oncode Accelerator
Accelerating the development of next-generation cancer therapies through collaboration and innovation. That is the mission of Oncode Accelerator. During the Oncode Accelerator Summit on December 4th, ...
www.oncodeaccelerator.nl
December 17, 2025 at 2:00 PM
Attivare Therapeutics (Wyss Institute spin-out) has joined Oncode Accelerator with a new Demonstrator Project, which MIMETAS is a key partner in.
Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
Together with Amsterdam UMC we’re working to improve translational oncology for hard-to-treat cancers. www.oncodeaccelerator.nl/news/wyss-in...
✨ Last Friday, MIMETAS wrapped up the year with our Christmas Party!
From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺
We’re grateful for the people and energy that make MIMETAS what it is.
#TeamCulture
From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺
We’re grateful for the people and energy that make MIMETAS what it is.
#TeamCulture
December 15, 2025 at 2:15 PM
✨ Last Friday, MIMETAS wrapped up the year with our Christmas Party!
From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺
We’re grateful for the people and energy that make MIMETAS what it is.
#TeamCulture
From dinner ➝ team-voted awards (Best Dressed, OrganoPlate Whisperer, PowerPoint Wizard, Energy Booster) ➝ dancing 💃🕺
We’re grateful for the people and energy that make MIMETAS what it is.
#TeamCulture
Proud to be featured by the Netherlands platform!
At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines.
🔗 Read the article: nlplatform.com/articles/-MI...
At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines.
🔗 Read the article: nlplatform.com/articles/-MI...
Transforming pharmaceuticals with Organ-on-a-Chip technology
For every drug that reaches the market, pharmaceutical companies invest time and effort in dozens, if not hundreds, of drugs that ultimately fail. Dutch biotechnology company MIMETAS, led by CEOs Jos ...
nlplatform.com
December 11, 2025 at 3:36 PM
Proud to be featured by the Netherlands platform!
At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines.
🔗 Read the article: nlplatform.com/articles/-MI...
At MIMETAS, we’re working to transform drug development with human-relevant in vitro models that better predict clinical outcomes – accelerating safer, more effective medicines.
🔗 Read the article: nlplatform.com/articles/-MI...
Model choice matters in liver disease research. Our webinar shows how MIMETAS 3D in-vitro liver models are used for fibrosis, steatosis & metabolic assays, incl. automated anti-fibrotic screening. Watch: shorturl.at/mpQPc
#LiverModel #Fibrosis #DrugDiscovery
#LiverModel #Fibrosis #DrugDiscovery
December 8, 2025 at 2:17 PM
Model choice matters in liver disease research. Our webinar shows how MIMETAS 3D in-vitro liver models are used for fibrosis, steatosis & metabolic assays, incl. automated anti-fibrotic screening. Watch: shorturl.at/mpQPc
#LiverModel #Fibrosis #DrugDiscovery
#LiverModel #Fibrosis #DrugDiscovery
This paper shows a microvascularized liver model with hepatocytes, stellate cells, and a self-organized perfusable endothelial plexus - native-like structure and HTS-ready robustness (excellent Z’). Big step for #MASH & anti-fibrotic screening research. Read here: shorturl.at/gOskI
#LiverOnAChip
#LiverOnAChip
November 27, 2025 at 3:25 PM
This paper shows a microvascularized liver model with hepatocytes, stellate cells, and a self-organized perfusable endothelial plexus - native-like structure and HTS-ready robustness (excellent Z’). Big step for #MASH & anti-fibrotic screening research. Read here: shorturl.at/gOskI
#LiverOnAChip
#LiverOnAChip
Looking for a physiologically relevant gut model in vitro? MIMETAS’ scalable 3D human gut models recreate key intestinal features, combining epithelium + perfused vasculature, stroma & immune components for more predictive barrier, ADME, toxicity & inflammation studies. shorturl.at/87E8x
November 25, 2025 at 2:29 PM
Looking for a physiologically relevant gut model in vitro? MIMETAS’ scalable 3D human gut models recreate key intestinal features, combining epithelium + perfused vasculature, stroma & immune components for more predictive barrier, ADME, toxicity & inflammation studies. shorturl.at/87E8x
❓How can we better model the human blood-brain barrier for CNS disease and drug development? From tight barrier formation to applications in stroke, neuroinflammation, toxicity testing, small-molecule transport, and antibody transcytosis - explore our 3D BBB-on-chip models: tinyurl.com/54wm4d4t
November 19, 2025 at 3:07 PM
❓How can we better model the human blood-brain barrier for CNS disease and drug development? From tight barrier formation to applications in stroke, neuroinflammation, toxicity testing, small-molecule transport, and antibody transcytosis - explore our 3D BBB-on-chip models: tinyurl.com/54wm4d4t
🚀 It’s here! We’re excited to unveil a fully redesigned website for MIMETAS. Built around how you explore science - from models and technology to screening, analysis, and ready-to-use tissues - all in one intuitive place. See for yourself: mimetas.com #OrganOnAChip #3DTissueModels #DrugDiscovery
November 18, 2025 at 1:29 PM
🚀 It’s here! We’re excited to unveil a fully redesigned website for MIMETAS. Built around how you explore science - from models and technology to screening, analysis, and ready-to-use tissues - all in one intuitive place. See for yourself: mimetas.com #OrganOnAChip #3DTissueModels #DrugDiscovery
🎓 Congrats to Dr. Murillo Bernardi on his successful PhD defense! His thesis, “From Chick to Chip - Novel models to bridge in vitro and in vivo kidney research” presents years of work on advancing predictive kidney models at UMC Utrecht and MIMETAS.
#PhDDefense #MIMETAS
#PhDDefense #MIMETAS
November 13, 2025 at 3:26 PM
🎓 Congrats to Dr. Murillo Bernardi on his successful PhD defense! His thesis, “From Chick to Chip - Novel models to bridge in vitro and in vivo kidney research” presents years of work on advancing predictive kidney models at UMC Utrecht and MIMETAS.
#PhDDefense #MIMETAS
#PhDDefense #MIMETAS
In this app note, learn how MIMETAS’ OrganoReady® Blood Vessel models enable high-throughput, human-relevant toxicity screening in 3D microfluidic blood vessel systems. Ultimately, this supports the development of safer therapeutics and better treatment strategies.
🔗 shorturl.at/gtn5M
🔗 shorturl.at/gtn5M
November 11, 2025 at 2:42 PM
In this app note, learn how MIMETAS’ OrganoReady® Blood Vessel models enable high-throughput, human-relevant toxicity screening in 3D microfluidic blood vessel systems. Ultimately, this supports the development of safer therapeutics and better treatment strategies.
🔗 shorturl.at/gtn5M
🔗 shorturl.at/gtn5M
New publication from BIOASTER! Using the OrganoPlate® platform and OrganoTEER® device, they built an immunocompetent intestinal model showing that Bifidobacterium infantis and Lacticaseibacillus rhamnosus GG protect the gut barrier from inflammation. www.mdpi.com/2673-8007/5/...
November 5, 2025 at 3:38 PM
New publication from BIOASTER! Using the OrganoPlate® platform and OrganoTEER® device, they built an immunocompetent intestinal model showing that Bifidobacterium infantis and Lacticaseibacillus rhamnosus GG protect the gut barrier from inflammation. www.mdpi.com/2673-8007/5/...